Athena Athena

X
[{"orgOrder":0,"company":"Teligent, Inc","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$45.8 million","upfrontCash":"Undisclosed","newsHeadline":"Hikma Expands Into Canada with Acquisition of Teligent Sterile Injectable Assets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Teligent, Inc

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.

            Lead Product(s): Atropine

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atropine-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: $45.8 million Upfront Cash: Undisclosed

            Deal Type: Acquisition January 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY